At Imagenomix Corp, we believe the future of cancer diagnostics is faster, smarter, and more accessible.
By combining AI-driven molecular analysis with digital pathology, we are working to reduce the time it takes to identify actionable cancer mutations from weeks to minutes — helping clinicians make faster decisions and expanding access to precision medicine worldwide.
We’re proud to continue advancing innovation alongside leading researchers, healthcare partners, and biotech collaborators as we build technology designed to improve patient outcomes and accelerate the future of oncology.
Original Post: https://www.linkedin.com/feed/update/urn:li:activity:7459394333104943105/